The Chhattisgarh government is reinforcing its commitment to providing quality healthcare by taking strict action against pharmaceutical companies that fail to meet quality standards. The latest move involves issuing a show-cause notice to M/s. Effi Parenterals, indicating that the company could be blacklisted due to issues with the quality of its drugs.
A key aspect of the health department’s quality control process is the rigorous testing of all drug batches supplied to health institutions. Random samples are sent to NABL-accredited labs, ensuring that only medicines that meet the required standards are distributed to patients.
In this instance, the State Drug Testing and Research Laboratory, Raipur, tested Albendazole tablets IP 400 mg (Drug Code – D12) from several batches (PGT25451, PGT25450, PGT25480, and PGT25229) supplied by M/s. Effi Parenterals. The tests revealed that these batches did not meet the necessary quality requirements. The health department is taking a firm stance and has issued a show-cause notice to the firm, which may result in blacklisting. The firm is also required to retrieve the substandard batches from the drug warehouses.
Before this incident, the same firm had provided 14 batches of Albendazole tablets IP 400 mg that were distributed after passing the required NABL tests.
